UK Markets close in 3 hrs 28 mins

Valneva SE (VALN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
22.70-1.24 (-5.18%)
At close: 04:00PM EDT
21.73 -0.97 (-4.27%)
Pre-market: 06:33AM EDT
Full screen
Loading interactive chart…
  • Motley Fool

    How Pfizer Plans to Unlock Another Mass-Market Vaccine

    As the first company to introduce a COVID-19 vaccine, pharmaceutical behemoth Pfizer (NYSE: PFE) experienced enormous windfalls by delivering primary and booster shots on a global scale. Now, Pfizer is developing a vaccine for another infectious disease with a wide-open market. Pfizer will invest about $95 million in specialty vaccine maker Valneva, based in France.

  • Globe Newswire

    Valneva SE Declaration of shares and voting rights - Interim status at June 22, 2022

    VALNEVA Declaration of shares and voting rights Interim status at June 22, 2022__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment A Declaration date: June 27, 2022 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on wh

  • Globe Newswire

    Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001

    VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe Saint Herblain (France), June 24, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva’s inactivated whole-virus COVID-19 vaccine, VLA2001, for use as primary vaccination in people from 18 to 50 years of age. With this approval, VLA2001 becomes the first COVID-1